Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

New potential players in hepcidin regulation.

Chappell M, Rivella S.

Haematologica. 2019 Sep;104(9):1691-1693. doi: 10.3324/haematol.2019.224311. No abstract available.

2.

Lobe specificity of iron-binding to transferrin modulates murine erythropoiesis and iron homeostasis.

Parrow NL, Li Y, Feola M, Guerra A, Casu C, Prasad P, Mammen L, Ali F, Vaicikauskas E, Rivella S, Ginzburg YZ, Fleming RE.

Blood. 2019 Aug 21. pii: blood.2018893099. doi: 10.1182/blood.2018893099. [Epub ahead of print]

PMID:
31434707
3.

Gene therapy of hemoglobinopathies: progress and future challenges.

Ikawa Y, Miccio A, Magrin E, Kwiatkowski JL, Rivella S, Cavazzana M.

Hum Mol Genet. 2019 Jul 19. pii: ddz172. doi: 10.1093/hmg/ddz172. [Epub ahead of print]

PMID:
31322165
4.

Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters.

Breveglieri G, Salvatori F, Finotti A, Cosenza LC, Zuccato C, Bianchi N, Breda L, Rivella S, Bresciani A, Bisbocci M, Borgatti M, Gambari R.

Anal Bioanal Chem. 2019 Jul 4. doi: 10.1007/s00216-019-01959-z. [Epub ahead of print]

PMID:
31273412
5.

Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia.

Guerra A, Oikonomidou PR, Sinha S, Zhang J, Lo Presti V, Hamilton CR, Breda L, Casu C, La P, Martins AC, Sendamarai AK, Fleming M, Rivella S.

Blood. 2019 Aug 8;134(6):568-572. doi: 10.1182/blood.2019001057. Epub 2019 May 31. No abstract available.

PMID:
31151988
6.

Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD.

Akchurin O, Patino E, Dalal V, Meza K, Bhatia D, Brovender S, Zhu YS, Cunningham-Rundles S, Perelstein E, Kumar J, Rivella S, Choi ME.

Kidney Int Rep. 2018 Dec 19;4(3):470-483. doi: 10.1016/j.ekir.2018.12.006. eCollection 2019 Mar.

7.

Genetic loss of Tmprss6 alters terminal erythroid differentiation in a mouse model of β-thalassemia intermedia.

Stagg DB, Whittlesey RL, Li X, Lozovatsky L, Gardenghi S, Rivella S, Finberg KE.

Haematologica. 2019 Feb 28. pii: haematol.2018.213371. doi: 10.3324/haematol.2018.213371. [Epub ahead of print]

8.

Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.

Ghiaccio V, Chappell M, Rivella S, Breda L.

Mol Diagn Ther. 2019 Apr;23(2):173-186. doi: 10.1007/s40291-019-00383-4. Review.

PMID:
30701409
9.

Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Rivella S.

Blood. 2019 Jan 3;133(1):51-58. doi: 10.1182/blood-2018-07-815928. Epub 2018 Nov 6. Review.

PMID:
30401707
10.

Hepcidin agonists as therapeutic tools.

Casu C, Nemeth E, Rivella S.

Blood. 2018 Apr 19;131(16):1790-1794. doi: 10.1182/blood-2017-11-737411. Epub 2018 Mar 9. Review.

11.

Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.

Agoro R, Montagna A, Goetz R, Aligbe O, Singh G, Coe LM, Mohammadi M, Rivella S, Sitara D.

FASEB J. 2018 Jul;32(7):3752-3764. doi: 10.1096/fj.201700667R. Epub 2018 Feb 26.

12.

Emerging Therapies.

Guerra A, Musallam KM, Taher AT, Rivella S.

Hematol Oncol Clin North Am. 2018 Apr;32(2):343-352. doi: 10.1016/j.hoc.2017.11.002. Epub 2017 Dec 15. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Jun;32(3):xiii.

13.

Ineffective Erythropoiesis: Anemia and Iron Overload.

Gupta R, Musallam KM, Taher AT, Rivella S.

Hematol Oncol Clin North Am. 2018 Apr;32(2):213-221. doi: 10.1016/j.hoc.2017.11.009. Epub 2017 Dec 29. Review.

14.

Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA, Vieth KR, Jung G, Casu C, Rivella S, Jormakka M, Mackenzie B, Ganz T, Nemeth E.

Blood. 2018 Feb 22;131(8):899-910. doi: 10.1182/blood-2017-05-786590. Epub 2017 Dec 13.

15.

Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.

Dong AC, Rivella S.

Adv Exp Med Biol. 2017;1013:155-176. doi: 10.1007/978-1-4939-7299-9_6. Review.

16.

Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.

Casu C, Presti VL, Oikonomidou PR, Melchiori L, Abdulmalik O, Ramos P, Rivella S.

Haematologica. 2018 Feb;103(2):e46-e49. doi: 10.3324/haematol.2017.181511. Epub 2017 Nov 2. No abstract available.

17.

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Taher AT, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A, Rivella S, Hollaender N, Mahuzier B, Gadbaw B, Aydinok Y.

Blood. 2018 Jan 11;131(2):263-265. doi: 10.1182/blood-2017-06-790121. Epub 2017 Nov 2. No abstract available.

18.

What can we learn from ineffective erythropoiesis in thalassemia?

Oikonomidou PR, Rivella S.

Blood Rev. 2018 Mar;32(2):130-143. doi: 10.1016/j.blre.2017.10.001. Epub 2017 Oct 3. Review.

19.

Red Blood Cells Homeostatically Bind Mitochondrial DNA through TLR9 to Maintain Quiescence and to Prevent Lung Injury.

Hotz MJ, Qing D, Shashaty MGS, Zhang P, Faust H, Sondheimer N, Rivella S, Worthen GS, Mangalmurti NS.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):470-480. doi: 10.1164/rccm.201706-1161OC.

20.

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.

Pasricha SR, Lim PJ, Duarte TL, Casu C, Oosterhuis D, Mleczko-Sanecka K, Suciu M, Da Silva AR, Al-Hourani K, Arezes J, McHugh K, Gooding S, Frost JN, Wray K, Santos A, Porto G, Repapi E, Gray N, Draper SJ, Ashley N, Soilleux E, Olinga P, Muckenthaler MU, Hughes JR, Rivella S, Milne TA, Armitage AE, Drakesmith H.

Nat Commun. 2017 Sep 1;8(1):403. doi: 10.1038/s41467-017-00500-z.

21.

Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome.

Nowak RB, Papoin J, Gokhin DS, Casu C, Rivella S, Lipton JM, Blanc L, Fowler VM.

Blood. 2017 Aug 31;130(9):1144-1155. doi: 10.1182/blood-2017-05-787051. Epub 2017 Jul 20.

22.

Recommendations regarding splenectomy in hereditary hemolytic anemias.

Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA.

Haematologica. 2017 Aug;102(8):1304-1313. doi: 10.3324/haematol.2016.161166. Epub 2017 May 26.

23.

Targeting iron metabolism in drug discovery and delivery.

Crielaard BJ, Lammers T, Rivella S.

Nat Rev Drug Discov. 2017 Jun;16(6):400-423. doi: 10.1038/nrd.2016.248. Epub 2017 Feb 3. Review.

24.

Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.

Li H, Choesang T, Bao W, Chen H, Feola M, Garcia-Santos D, Li J, Sun S, Follenzi A, Pham P, Liu J, Zhang J, Ponka P, An X, Mohandas N, Fleming RE, Rivella S, Li G, Ginzburg YZ.

Blood. 2017 Mar 16;129(11):1514-1526. doi: 10.1182/blood-2016-09-742387. Epub 2017 Feb 1. Erratum in: Blood. 2017 Dec 21;130(25):2809.

25.

A Red Carpet for Iron Metabolism.

Muckenthaler MU, Rivella S, Hentze MW, Galy B.

Cell. 2017 Jan 26;168(3):344-361. doi: 10.1016/j.cell.2016.12.034. Review.

26.

Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt.

Han CY, Koo JH, Kim SH, Gardenghi S, Rivella S, Strnad P, Hwang SJ, Kim SG.

Nat Commun. 2016 Dec 22;7:13817. doi: 10.1038/ncomms13817.

27.

Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.

Akchurin O, Sureshbabu A, Doty SB, Zhu YS, Patino E, Cunningham-Rundles S, Choi ME, Boskey A, Rivella S.

Am J Physiol Renal Physiol. 2016 Nov 1;311(5):F877-F889. doi: 10.1152/ajprenal.00089.2016. Epub 2016 Jul 20.

28.

A validated cellular biobank for β-thalassemia.

Cosenza LC, Breda L, Breveglieri G, Zuccato C, Finotti A, Lampronti I, Borgatti M, Chiavilli F, Gamberini MR, Satta S, Manunza L, De Martis FR, Moi P, Rivella S, Gambari R, Bianchi N.

J Transl Med. 2016 Sep 2;14:255. doi: 10.1186/s12967-016-1016-4.

29.

Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers.

Breda L, Motta I, Lourenco S, Gemmo C, Deng W, Rupon JW, Abdulmalik OY, Manwani D, Blobel GA, Rivella S.

Blood. 2016 Aug 25;128(8):1139-43. doi: 10.1182/blood-2016-01-691089. Epub 2016 Jul 12.

30.

Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.

Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, Fleming RE, Shah YM, Valore EV, Nemeth E, Ganz T, MacDonald B, Rivella S.

Blood. 2016 Jul 14;128(2):265-76. doi: 10.1182/blood-2015-10-676742. Epub 2016 May 6.

31.

New strategies to target iron metabolism for the treatment of beta thalassemia.

Oikonomidou PR, Casu C, Rivella S.

Ann N Y Acad Sci. 2016 Mar;1368(1):162-8. doi: 10.1111/nyas.13018. Epub 2016 Feb 25. Review.

32.

HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors.

Valdés-Ferrer SI, Papoin J, Dancho ME, Olofsson PS, Li J, Lipton JM, Avancena P, Yang H, Zou YR, Chavan SS, Volpe BT, Gardenghi S, Rivella S, Diamond B, Andersson U, Steinberg BM, Blanc L, Tracey KJ.

Mol Med. 2016 May;21(1):951-958. doi: 10.2119/molmed.2015.00243. Epub 2015 Dec 29.

33.

Polycythemia is associated with bone loss and reduced osteoblast activity in mice.

Oikonomidou PR, Casu C, Yang Z, Crielaard B, Shim JH, Rivella S, Vogiatzi MG.

Osteoporos Int. 2016 Apr;27(4):1559-1568. doi: 10.1007/s00198-015-3412-7. Epub 2015 Dec 9.

34.

Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation.

Chen H, Choesang T, Li H, Sun S, Pham P, Bao W, Feola M, Westerman M, Li G, Follenzi A, Blanc L, Rivella S, Fleming RE, Ginzburg YZ.

Haematologica. 2016 Mar;101(3):297-308. doi: 10.3324/haematol.2015.127902. Epub 2015 Dec 3.

35.

Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.

Casu C, Aghajan M, Oikonomidou PR, Guo S, Monia BP, Rivella S.

Haematologica. 2016 Jan;101(1):e8-e11. doi: 10.3324/haematol.2015.133348. Epub 2015 Sep 24. No abstract available.

36.

Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2α Improves Anemia in Sickle Cell Disease.

Das N, Xie L, Ramakrishnan SK, Campbell A, Rivella S, Shah YM.

J Biol Chem. 2015 Sep 25;290(39):23523-7. doi: 10.1074/jbc.C115.681643. Epub 2015 Aug 19.

37.

Generation and Characterization of a Transgenic Mouse Carrying a Functional Human β -Globin Gene with the IVSI-6 Thalassemia Mutation.

Breveglieri G, Mancini I, Bianchi N, Lampronti I, Salvatori F, Fabbri E, Zuccato C, Cosenza LC, Montagner G, Borgatti M, Altruda F, Fagoonee S, Carandina G, Rubini M, Aiello V, Breda L, Rivella S, Gambari R, Finotti A.

Biomed Res Int. 2015;2015:687635. doi: 10.1155/2015/687635. Epub 2015 May 4.

38.

β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Rivella S.

Haematologica. 2015 Apr;100(4):418-30. doi: 10.3324/haematol.2014.114827. Review.

39.

Recent trends in the gene therapy of β-thalassemia.

Finotti A, Breda L, Lederer CW, Bianchi N, Zuccato C, Kleanthous M, Rivella S, Gambari R.

J Blood Med. 2015 Feb 19;6:69-85. doi: 10.2147/JBM.S46256. eCollection 2015. Review.

40.

Iron age: novel targets for iron overload.

Casu C, Rivella S.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):216-21. doi: 10.1182/asheducation-2014.1.216. Epub 2014 Nov 18. Review.

41.

Altered erythropoiesis and iron metabolism in carriers of thalassemia.

Guimarães JS, Cominal JG, Silva-Pinto AC, Olbina G, Ginzburg YZ, Nandi V, Westerman M, Rivella S, de Souza AM.

Eur J Haematol. 2015 Jun;94(6):511-8. doi: 10.1111/ejh.12464. Epub 2014 Nov 11.

42.

Alternative splicing of EKLF/KLF1 in murine primary erythroid tissues.

Yien YY, Gnanapragasam MN, Gupta R, Rivella S, Bieker JJ.

Exp Hematol. 2015 Jan;43(1):65-70. doi: 10.1016/j.exphem.2014.08.007. Epub 2014 Oct 2.

43.

Reactivation of developmentally silenced globin genes by forced chromatin looping.

Deng W, Rupon JW, Krivega I, Breda L, Motta I, Jahn KS, Reik A, Gregory PD, Rivella S, Dean A, Blobel GA.

Cell. 2014 Aug 14;158(4):849-860. doi: 10.1016/j.cell.2014.05.050.

44.

FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.

Zhang X, Campreciós G, Rimmelé P, Liang R, Yalcin S, Mungamuri SK, Barminko J, D'Escamard V, Baron MH, Brugnara C, Papatsenko D, Rivella S, Ghaffari S.

Am J Hematol. 2014 Oct;89(10):954-63. doi: 10.1002/ajh.23786. Epub 2014 Jul 22.

45.

Identification of erythroferrone as an erythroid regulator of iron metabolism.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T.

Nat Genet. 2014 Jul;46(7):678-84. doi: 10.1038/ng.2996. Epub 2014 Jun 1.

46.

Cancer cells with irons in the fire.

Bystrom LM, Rivella S.

Free Radic Biol Med. 2015 Feb;79:337-42. doi: 10.1016/j.freeradbiomed.2014.04.035. Epub 2014 May 14. Review.

47.

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.

Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R.

Blood. 2014 Jun 19;123(25):3864-72. doi: 10.1182/blood-2013-06-511238. Epub 2014 May 2.

48.

β-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis.

Crielaard BJ, Rivella S.

Int J Biochem Cell Biol. 2014 Jun;51:89-92. doi: 10.1016/j.biocel.2014.03.029. Epub 2014 Apr 6. Review. Erratum in: Int J Biochem Cell Biol. 2014 Oct;55:349.

49.

Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations.

Martin L, Grigoryan A, Wang D, Wang J, Breda L, Rivella S, Cardozo T, Gardner LB.

Cancer Res. 2014 Jun 1;74(11):3104-13. doi: 10.1158/0008-5472.CAN-13-2235. Epub 2014 Mar 24.

50.

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Breda L, Rivella S.

Hematol Oncol Clin North Am. 2014 Apr;28(2):375-86. doi: 10.1016/j.hoc.2013.12.001. Epub 2014 Jan 18. Review.

Supplemental Content

Loading ...
Support Center